| Style | Citing Format |
|---|---|
| MLA | Etemadifar M, et al.. "Incidence and Clinical Characteristics of Amyotrophic Lateral Sclerosis During the Post-Covid-19 Period: A Population-Based Study From Isfahan, Iran." Neurodegenerative Disease Management, vol. , no. , 2026, pp. -. |
| APA | Etemadifar M, Salari M, Kashefi M, Shams Y, Heydari Sichani M, Hojjatipour F (2026). Incidence and Clinical Characteristics of Amyotrophic Lateral Sclerosis During the Post-Covid-19 Period: A Population-Based Study From Isfahan, Iran. Neurodegenerative Disease Management, (), -. |
| Chicago | Etemadifar M, Salari M, Kashefi M, Shams Y, Heydari Sichani M, Hojjatipour F. "Incidence and Clinical Characteristics of Amyotrophic Lateral Sclerosis During the Post-Covid-19 Period: A Population-Based Study From Isfahan, Iran." Neurodegenerative Disease Management , no. (2026): -. |
| Harvard | Etemadifar M et al. (2026) 'Incidence and Clinical Characteristics of Amyotrophic Lateral Sclerosis During the Post-Covid-19 Period: A Population-Based Study From Isfahan, Iran', Neurodegenerative Disease Management, (), pp. -. |
| Vancouver | Etemadifar M, Salari M, Kashefi M, Shams Y, Heydari Sichani M, Hojjatipour F. Incidence and Clinical Characteristics of Amyotrophic Lateral Sclerosis During the Post-Covid-19 Period: A Population-Based Study From Isfahan, Iran. Neurodegenerative Disease Management. 2026;():-. |
| BibTex | @article{ author = {Etemadifar M and Salari M and Kashefi M and Shams Y and Heydari Sichani M and Hojjatipour F}, title = {Incidence and Clinical Characteristics of Amyotrophic Lateral Sclerosis During the Post-Covid-19 Period: A Population-Based Study From Isfahan, Iran}, journal = {Neurodegenerative Disease Management}, volume = {}, number = {}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Etemadifar M AU - Salari M AU - Kashefi M AU - Shams Y AU - Heydari Sichani M AU - Hojjatipour F TI - Incidence and Clinical Characteristics of Amyotrophic Lateral Sclerosis During the Post-Covid-19 Period: A Population-Based Study From Isfahan, Iran JO - Neurodegenerative Disease Management VL - IS - SP - EP - PY - 2026 ER - |